Companies › Georgiamune
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GIM-122 Humanized IgG1 kappa dual functioning monoclonal antibody (DFA) | – | Phase 1 | Advanced Solid Malignancies | Dec 2026 |
| GIM-531 Selective regulatory T-cell (Treg) inhibitor | – | Phase 1 | Melanoma Stage IV | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06425926 | GIM-531 | Phase 1 | Melanoma Stage IV | Oncology | Dec 2026 |
| NCT06028074 | GIM-122 | Phase 1 | Advanced Solid Malignancies | Oncology | Dec 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.